Intelligence · Clinical Pipeline
Metabolic & obesity · Approved programs
Metabolic & obesity programs at Approved programs — ClinicalTrials.gov pipeline intelligence.
- Programs
- 105
Quick answer
Metabolic & obesity Approved programs programs: NovaPharmaNews indexes 105 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- Takeda 21 programs
- First People's Hospital 15 programs
- Disc Medicine 7 programs
- Regeneron UK 7 programs
- George Institute for 5 programs
- Chinese Academy of 4 programs
- Hospital Authority 4 programs
- Sanofi Pasteur MSD 4 programs
- ANI PHARMACEUTICALS 3 programs
- Eli Lilly and 3 programs
- HALOZYME THERAPEUTICS 3 programs
- NovoThirteen 3 programs
-
glargine + exenatide
Hong Kong Baptist University
Type 2 Diabetes Mellitus
1 trial -
insulin detemir
Novo Nordisk A/S
Diabetes
2 trials -
insulin lispro injection, exenatide injection
The First People's Hospital of Lianyungang
Diabetes Mellitus, Type 2
1 trial -
metformin
Boehringer Ingelheim
Diabetes Mellitus, Type 2
1 trial -
pioglitazone
Takeda
Type 2 Diabetes Mellitus
4 trials -
pioglitazone
GlaxoSmithKline
Diabetes Mellitus, Type 2
1 trial -
pioglitazone
Takeda
Type 2 Diabetes
1 trial -
pregabalin
Pfizer
Diabetic Neuropathy, Painful
1 trial -
premeal insulin lispro mixtures
Eli Lilly and Company
Diabetes Mellitus, Type 2
1 trial
Frequently asked questions
How many metabolic & obesity Approved programs programs exist?
105 programs match both the therapeutic area and stage filters in our published index.
Data attribution: Data sources · All pipeline programs